Rechercher des projets européens

11 projets européens trouvés

Recherche sur 125080 projets européens

 TERMINÉ 

Children’s Liver Tumour European Research Network (ChiLTERN)

Date du début: 1 janv. 2016, Date de fin: 31 déc. 2020,

Liver cancer in the paediatric population is rare with an incidence approximately 1-1.5 per million population. The commonest tumour seen in the childhood population is hepatoblastoma (HB), usually seen in young children and infants. Much rarer (about 10% of paediatric liver cancers) is hepatocellular carcinoma (HCC), usually seen in the teenage population and sometimes associated with underlying ...
Voir le projet

 21

 TERMINÉ 

TBVAC2020; Advancing novel and promising TB vaccine candidates from discovery to preclinical and early clinical development (TBVAC2020)

Date du début: 1 janv. 2015, Date de fin: 31 déc. 2018,

The TBVAC2020 proposal builds on the highly successful and long-standing collaborations in subsequent EC-FP5-, FP6- and FP7-funded TB vaccine and biomarker projects, but also brings in a large number of new key partners from excellent laboratories from Europe, USA, Asia, Africa and Australia, many of which are global leaders in the TB field. This was initiated by launching an open call for Express ...
Voir le projet

 49

 TERMINÉ 

Eliciting Mucosal Immunity to Tuberculosis (EMI-TB)

Date du début: 1 janv. 2015, Date de fin: 31 déc. 2018,

Tuberculosis (TB) is a global health problem, killing 1.5 million of people every year. The only currently available vaccine, Mycobacterium bovis BCG, is effective against severe childhood forms, but it demonstrates a variable efficacy against the pulmonary form of TB in adults. Many of these adult TB cases result from the reactivation of an initially controlled, latent Mycobacterium tuberculosis ...
Voir le projet

 15

 TERMINÉ 

Towards the elimination of iodine deficiency and preventable thyroid-related diseases in Europe (EUthyroid)

Date du début: 1 juin 2015, Date de fin: 31 mai 2018,

Despite the fact that iodine deficiency (ID) can easily be prevented by iodine fortification of table salt, industrial salt and cattle food, Europe belongs to the worst regions in terms of access to iodized salt and is seriously ID, resulting in the perpetuation of the single most important, preventable cause of brain damage. European ID is due to significant heterogeneity in prevention and monito ...
Voir le projet

 33

 TERMINÉ 

A progress of tuberculosis and HIV/tuberculosis treatment assessed by fingerprinting of small molecule-biomarkers in patients from Eastern Europe (TB prognosis)

Date du début: 1 avr. 2013, Date de fin: 31 mars 2017,

A dramatically high incidence of multidrug-resistant (MDR) and extended drug resistant (XDR) tuberculosis (TB) was reported in WHO European Region. Countries in Eastern Europe still fail to control TB and in, for example, Ukraine, a number of new TB cases is as high as 100-299 per 100 000 (data for 2010). TB is often accompanied by HIV on this territory. In EU countries, patients with MDR and XDR- ...
Voir le projet

 2

 TERMINÉ 

Identifying new Markers and Homing Profiles involved in Lymphocyte Migration to the Female Reproductive Tract (FRT-homing)

Date du début: 1 avr. 2012, Date de fin: 17 sept. 2016,

The effort to develop vaccines that can elicit mucosal immune responses in the female reproductive tract (FRT) against sexually transmitted infections (STI) have been hampered by an inability to accurately measure immune responses in the genital tract. Vaccines against STIs should generate localized memory responses at sites of potential exposure to provide better control of infection. Critically, ...
Voir le projet

 1

 TERMINÉ 

Discovery and preclinical development of new generation tuberculosis vaccines (NEWTBVAC)

Date du début: 1 janv. 2010, Date de fin: 28 févr. 2014,

"With 14.4 million prevalent cases and 1.7 million deaths tuberculosis (TB) remains one of the most serious infectious diseases to date. An estimated 2 billion people are believed to be infected with Mycobacterium tuberculosis and at risk of developing disease. Multi- and extensively drug resistant strains are increasingly appearing in many parts of the world, including Europe. While with current ...
Voir le projet

 39

 TERMINÉ 

Compliance and effectiveness in HF and CHD closed-loop management (HeartCycle)

Date du début: 1 mars 2008, Date de fin: 31 août 2013,

Each year Cardiovascular Disease (CVD) causes over 1.9 million deaths in the EU, causing direct health costs of €105 billion. Coronary Heart Disease (CHD), half of all CVD deaths, is the single most cause of death in Europe. Heart Failure (HF) – a CHD being the most frequent cause of hospitalization for people over 65 – has 10 million patients in the EU. Current treatment of HF entails recommendat ...
Voir le projet

 22

 TERMINÉ 

Novel strategies for the prevention and control of persistent infections (NOPERSIST)

Date du début: 1 janv. 2010, Date de fin: 31 déc. 2012,

"Persistent infections such as HIV, tuberculosis´(TB) in humans and para-tuberculosis (ParaTB)-, mycoplasma- and Haemophilus-infections in farm animals are global health problems of immense social and economic importance . HIV-1 affects about 40 million people and M. tuberculosis infection is even higher world-wide. Co-infection with M. tuberculosis is estimated in about one-third of HIV-1 infecte ...
Voir le projet

 12

 TERMINÉ 

Regeneration of Cardiac Tissue Assisted by Bioactive Implants (RECATABI)

Date du début: 1 janv. 2010, Date de fin: 31 déc. 2012,

Heart failure is the end-stage of many cardiovascular diseases, but the leading cause is the presence of a large scar due acute to myocardial infarction. Current therapeutic treatments under development consist in cellular cardiomyoplasty where myocardial cells or stem cells are implanted alone or encapsulated in natural scaffolds (collagens) and grafted onto infarcted ventricles with the hope tha ...
Voir le projet

 7

 TERMINÉ 

LATENT TUBERCULOSIS: New tools for the detection and clearance of dormant Mycobacterium tuberculosis (STOPLATENT-TB)

Date du début: 1 févr. 2008, Date de fin: 31 juil. 2011,

Although the definition of latency under a clinical point of view seems clear, the bacterial biology behind that clinical situation remains poorly understood. While dormant, the tubercle bacilli are considered to be under non-replicating (NR) stage. In such a condition, bacilli are not only difficult to be detected but also refractory to the standard treatments avoiding their clearance from the in ...
Voir le projet

 7